BDBM451802 US10710980, Example 34::US10947218, Example 34

SMILES Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@@]12C[C@@H]1CN(C2)C1CCOCC1

InChI Key InChIKey=KPRPFTOLWQQUAV-OCVAFRRMSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 451802   

TargetActivin receptor type-1 [172-499](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  18nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A [198-525](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  914nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetActivin receptor type-1 [172-499](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  23nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetActivin receptor type-1 [172-499,R206H](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  21nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3 [166-493](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  323nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  6.28E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  3.30E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetActivin receptor type-1 [172-499](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  18nMAssay Description:A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A [198-525](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  914nMAssay Description:A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetActivin receptor type-1 [172-499](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  23nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetActivin receptor type-1 [172-499,R206H](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  21nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3 [166-493](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  323nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTGF-beta receptor type-1 [162-503](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  6.28E+3nMAssay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM451802(US10710980, Example 34 | US10947218, Example 34)
Affinity DataIC50:  3.30E+3nMAssay Description:In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1...More data for this Ligand-Target Pair
In DepthDetails US Patent